Ankaferd Blood Stopper
Chemotherapy-Induced Toxicity
Explore 63 assets in Chemotherapy-Induced Toxicity →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Uludag University
Modality
UNKNOWN
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Toxicity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ankaferd Blood Stopper (this asset) | Uludag University | N/A | D · 30 |
| Palonosetron | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Dexasone | Instituto do Cancer do Estado de São Paulo | P4 | BBB |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BB |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BB |
| Netupitant | Instituto Brasileiro de Controle do Cancer | P3 | BB |
| HR20013 | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Endeavor Health | P3 | BB |
| Oxaliplatin | Linhui Peng | P3 | B |
+42 more in the Chemotherapy-Induced Toxicity cohort
Other indications for Ankaferd Blood Stopper
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | Early P1 | C · 39 |
| Stomatitis | — | N/A | D · 30 |
| Colon Carcinoma | — | N/A | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- DexasoneInstituto do Cancer do Estado de São PauloBBB
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBB
- DocetaxelThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBB
- NetupitantInstituto Brasileiro de Controle do CancerBB
Citation
Floatz Terminal. Ankaferd Blood Stopper in Chemotherapy-Induced Toxicity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ankaferd-blood-stopper-chemotherapy-induced-toxicity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →